 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 July 1996 | Volume 125 Issue 1 | Pages 1-7
Background: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented.
Objective: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis.
Design: Prospective cohort study.
Setting: University outpatient thrombosis clinic.
Patients: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis.
Measurements: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated.
Results: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1).
Conclusion: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.
The long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae in patients with symptomatic deep venous thrombosis have not been well documented. In a recent large randomized, clinical trial comparing 6 weeks of oral anticoagulant therapy with 6 months of therapy [6], patients with symptomatic deep venous thrombosis were followed for 2 years for recurrences and death. This trial showed a substantial reduction in the risk for recurrent venous thromboembolism among patients in the 6-month oral anticoagulant group, but the investigators did not report on the occurrence of the post-thrombotic syndrome. Another recent study [7] reported the 8-year incidence of recurrences and post-thrombotic manifestations in patients with confirmed symptomatic deep venous thrombosis. However, only a few patients were included in this study, and data were collected retrospectively.
We assessed the clinical course of a first episode of symptomatic deep venous thrombosis in a large consecutive series of patients who had long-term follow-up. We assessed mortality and the long-term incidences of recurrent venous thromboembolism and the post-thrombotic syndrome. We also evaluated the potential risk factors for these three outcomes.
The Department of Internal Medicine of the University of Padua, Padua, Italy, is a diagnostic facility for outpatients with clinically suspected venous thromboembolism in a community of approximately 350 000 persons. All consecutive outpatients with a first episode of clinically suspected deep venous thrombosis who were referred by their general practitioners between January 1986 and December 1991 had noninvasive testing [8]. Patients were potentially eligible for the study if confirmatory venography showed deep venous thrombosis. Patients were excluded from the study if they had been referred because of recurrent venous thrombosis, were geographically inaccessible for follow-up, or refused to give informed consent. The Institutional Review Board of the hospital of the University of Padua approved the study.
Baseline Assessment
At the time of referral, demographic characteristics were recorded and a medical history was taken; information was elicited on the period between the onset of symptoms and presentation to the thrombosis service (patient–physician delay), the presence of risk factors for thrombosis (that is, cancer, surgery, trauma or fracture, immobilization for more than 7 days, pregnancy or childbirth, or estrogen use), and symptoms of pulmonary embolism. Information was also obtained on the history of venous thromboembolism in first-degree relatives. Antithrombin, protein C and S, and lupus-like anticoagulant levels were subsequently measured. Assays were done, and previously described criteria for abnormality and deficiency were used [9].
The venograms obtained at baseline were divided into those representing proximal venous thrombosis (with or without concurrent venous thrombosis of the calf) and those indicating isolated venous thrombosis of the calf. Proximal venous thrombosis was defined as thrombosis located above the trifurcation of the calf veins that involved at least the popliteal vein, superficial femoral vein, common femoral vein, or iliac vein. The location and occlusiveness of proximal thrombi were also determined. A patient was considered to have nonocclusive deep venous thrombosis if contrast material was seen between the thrombus and the vessel wall along the entire thrombus.
Treatment
Patients were admitted to the hospital and treated with an initial course of high-dose intravenous standard heparin (a bolus of 5000 U followed by continuous infusion of 30 000 U/d, subsequently adjusted to maintain an activated partial thromboplastin time between 1.5 and 2.5 times the normal value) or subcutaneous low-molecular-weight heparin (90 U of anti-factor Xa/kg of body weight twice daily). Therapy with oral anticoagulant agents (warfarin) was started on day 5 to 7 of treatment and was continued for 3 months. The oral anticoagulant dose was adjusted daily to maintain an international normalized ratio between 2.0 and 3.0. Treatment with low-molecular-weight heparin was discontinued on day 10 or later if the international normalized ratio was less than 2.0. This treatment strategy deviated in the following groups of patients: those with cancer, protein deficiencies, or lupus anticoagulant, in whom oral anticoagulation therapy was prolonged; those with small isolated venous thrombosis of the calf, who received oral anticoagulation alone; those with contraindications to anticoagulant treatment, who received no treatment or an inferior caval-vein filter; those who refused to be hospitalized, who received low-dose heparin and oral anticoagulant agents; and those with threatened viability of the leg, who received thrombolytic therapy. The actual type and duration of treatments were recorded. All patients were instructed to wear elastic graduated compression stockings (providing 40 mm Hg of pressure at the ankle) for at least 2 years.
Follow-up
All patients were seen 3 and 6 months after the initial referral and thereafter returned to the study center every 6 months for follow-up assessments. Patients were asked to return to the thrombosis center immediately if symptoms suggestive of recurrent venous thromboembolism developed. Follow-up was continued for as long as 8 years or until July 1995. To avoid diagnostic suspicion bias, the medical history on general health, symptoms of recurrent venous thromboembolism, and the post-thrombotic syndrome was obtained by using a standardized form. Patients who could not attend the follow-up sessions were visited at home. For all patients who died during follow-up, the date and cause of death were documented.
Diagnosis of Recurrent Venous Thromboembolism and Hemorrhage
Contrast venography of the symptomatic leg or legs was done as described previously [10]. The criteria for deep venous thrombosis were a constant intraluminal filling defect confirmed in at least two different projections or nonvisualization of a vein or a segment thereof, despite adequate technique and repeated injections with contrast material. The presence or absence of venous thrombosis was assessed by a panel of independent observers who were unaware of the patient's other clinical features or previous test results. If a patient presented with clinically suspected recurrent venous thrombosis of the leg, venography was done. The criterion for recurrent venous thrombosis of the leg was a new intraluminal filling defect on the venogram. If the venogram was not diagnostic, recurrent venous thrombosis was diagnosed on the basis of an abnormal 125I-fibrinogen leg scan or results of noninvasive tests that had changed from normal to abnormal [11, 12]. Patients with suspected pulmonary embolism had venography if they had concurrent leg symptoms or perfusion lung scanning in the absence of leg symptoms. Pulmonary embolism was excluded if the perfusion scan was normal. Because ventilation lung scanning was not available during the first years of the study and because pulmonary angiography could not routinely be done, we could not definitively diagnose pulmonary embolism in some patients. If a definitive diagnosis could not be made, patients were classified as not having recurrent venous thromboembolism. Perfusion lung scanning and pulmonary angiography were done and their results were interpreted according to standard procedures [13]. Hemorrhagic episodes were classified as major or minor, as reported previously [14]. The documentation of all patients suspected of having a recurrent venous thromboembolic or bleeding event was reviewed by a three-member adjudication committee that was unaware of further clinical details of the patient.
Criteria for the Post-Thrombotic Syndrome
Presence of the post-thrombotic syndrome was assessed by investigators who were unaware of previous post-thrombotic manifestations and further clinical details of the patient. The presence of leg symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and signs (pretibial edema, induration of the skin, hyperpigmentation, new venous ectasia, redness, and pain during calf compression) was scored. For each item, the investigators assigned a score of 0 (not present or minimal) to 3 (severe). The presence of a venous ulcer of the lower limb was recorded. In patients with bilateral thrombosis, the higher score was used. A total score of 15 or more on two consecutive visits or the presence of a venous ulcer indicated severe post-thrombotic syndrome, and a total score of 5 to 14 on two consecutive visits indicated mild post-thrombotic syndrome. This score has been shown to have good reproducibility, and it correlates well with the patient's perception of the interference of leg symptoms with daily life [15].
Statistical Analysis
We calculated Kaplan-Meier estimates and 95% CIs for a visual assessment of survival and calculated the risk for recurrent venous thromboembolism and mild and severe post-thrombotic syndrome. Using the stepwise Cox proportional-hazards model, we calculated the hazard ratios for death, recurrent venous thromboembolism, and mild and severe post-thrombotic syndrome associated with various clinical features [16]. In each case, we used the duration of oral anticoagulant treatment as a time-dependent variable for recurrent venous thromboembolism and death. The occurrence of a recurrent event in the same leg was used as a time-dependent variable for mild and severe post-thrombotic syndrome. We expressed the results of these analyses as hazard ratios and 95% CIs. Because death is a competing risk for recurrent venous thromboembolism and the post-thrombotic syndrome, our estimated hazard ratios for these outcomes refer to the hazards that would exist if death could be removed as a competing risk. Our analysis also assumes that death is statistically independent of these outcomes. ARTICLE
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Deep venous thrombosis of the lower extremity is a serious disorder; the estimated incidence is 1 per 1000 persons per year [1-3]. The disease can occur after surgical procedures and trauma and in the presence of cancer or inherited coagulation disorders; it can also develop without any of these factors [3]. The clinical course of deep venous thrombosis might be complicated by pulmonary embolism, recurrent episodes of deep venous thrombosis, and the development of serious post-thrombotic sequelae, such as venous ulceration, debilitating pain, and intractable edema [3]. Patients with deep venous thrombosis are usually treated with an initial course of heparin (5 to 10 days) followed by 3 to 6 months of oral anticoagulant therapy. This treatment regimen reduces the risk for short-term thromboembolic complications to approximately 5% [4, 5].
Methods
Top
Methods
Results
Discussion
Author & Article Info
References
Identification of Inception Cohort
Results
Top
Methods
Results
Discussion
Author & Article Info
References
Three hundred fifty-five consecutive patients with a first episode of venography-confirmed deep venous thrombosis were included in our study. The demographic and clinical characteristics and prevalence of potential risk factors are presented in Table 1. Two hundred forty-five patients (69%) completed 5 years of follow-up, and 148 patients (42%) completed 8 years of follow-up. Thirteen patients (3.7%) were lost to follow-up after 2 to 7 years.
|
Recurrent Venous Thromboembolism
Of the 355 patients, 78 had one or more documented recurrent venous thromboembolic events. Thirty-five first recurrences (44.9%) occurred in the leg that had been initially involved, 28 (35.9%) occurred in the contralateral leg, and 15 (19.2%) were pulmonary emboli. The pulmonary emboli were fatal in 9 patients (11.5%); in 7 of these 9 patients, the diagnosis was based on autopsy findings. The cumulative incidence of recurrent venous thromboembolism was 4.9% after 3 months (95% CI, 2.6% to 7.1%) and 8.6% after 6 months (CI, 5.6% to 11.6%). This incidence gradually increased to 17.5% (CI, 13.6% to 22.2%) after 2 years of follow-up, 24.6% (CI, 19.6% to 29.7%) after 5 years of follow-up, and 30.3% (CI, 23.6% to 37.0%) after 8 years of follow-up (Figure 1). Among the evaluated potential risk factors and clinical characteristics, the presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively).
|
The Post-Thrombotic Syndrome
Eighty-four patients developed the post-thrombotic syndrome. Of these, 25 (30.2%) had severe post-thrombotic manifestations. The cumulative incidence of the post-thrombotic syndrome was 17.3% (CI, 14.6% to 23.5%) after 1 year of follow-up and 22.8% (CI, 18.0% to 27.5%) after 2 years of follow-up. The cumulative incidence increased gradually to 28.0% (CI, 22.7% to 33.3%) after 5 years but did not substantially change thereafter (29.1% at 8 years; CI, 23.4% to 34.7%) (Figure 2). When only severe post-thrombotic manifestations are considered, a different pattern is seen in the first 5 years of follow-up, because the cumulative incidence increased gradually from 2.6% (CI, 0.8% to 4.4%) after 1 year to 9.3% (CI, 5.6% to 12.8%) after 5 years. Thereafter, the cumulative incidence of severe post-thrombotic manifestations did not increase (Figure 2).
|
The development of ipsilateral recurrent deep venous thrombosis was associated with an increased risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). No significant associations were seen between the occurrence of the post-thrombotic syndrome and the presence of thrombi in the popliteal vein (hazard ratio, 1.2), occlusive thrombi (hazard ratio, 0.8), or the extent of thrombosis (hazard ratio, 1.1). When ipsilateral recurrent deep venous thrombosis was included in the analysis, none of the other clinical features showed a significant association with the risk for the post-thrombotic syndrome.
Other Clinical Events
Forty-seven patients developed a hemorrhagic complication. The complication was major in 17 of these patients and fatal in 2 of the 17. Nineteen of the hemorrhagic episodes (6 of which were major) occurred during the initial 14-day treatment period, for a cumulative incidence of 5.1% (CI, 2.8% to 7.4%). Another 16 hemorrhages (5 of which were major) occurred between days 14 and 90, for a cumulative incidence at 3 months of 9.8% (CI, 6.7% to 13.0%). Of the 47 patients who continued to receive treatment with oral anticoagulants after 3 months, 12 developed a hemorrhage during long-term follow-up (6 of these 12 had a major episode).
Malignant disease became apparent during follow-up in 26 of the 297 patients who had no cancer at baseline. Cancer developed primarily in patients with unexplained deep venous thrombosis at baseline, as reported previously [17]. Sixteen patients had an ischemic stroke during follow-up; the stroke was fatal in 10 of these patients.
Mortality
Ninety patients died during follow-up. Fifty-four of the 84 patients in whom cancer was diagnosed at baseline or during follow-up died. Thirty-four of the 58 patients with cancer at baseline died during the first year after the thrombotic episode. The causes of death included cancer (n = 52), ischemic stroke (n = 10), acute myocardial infarction (n = 2), pulmonary embolism (n = 9), heart failure (n = 3), anticoagulant-related hemorrhage (n = 2), and miscellaneous conditions (n = 6). In 6 patients who died suddenly, a definite diagnosis could not be made.
Survival was 83.3% (CI, 79.4% to 87.3%) after 1 year of follow-up, 80.1% (CI, 75.9% to 84.3%) after 2 years, 74.6% after 5 years, and 70.2% after 8 years (Figure 3). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1). No other clinical features were associated with death.
|
Discussion
|
|---|
|
TopMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
The post-thrombotic syndrome occurred in approximately 30% of patients. However, the cumulative incidence of severe post-thrombotic manifestations after 8 years of follow-up was less than 10%. This is in contrast with the results of small studies, in which post-thrombotic sequelae were seen in as many as 90% of patients [18-24]. However, the systematic use of graduated compression stockings could have contributed to this relatively low incidence, as shown by a recent controlled study [25]. In many patients (65%), manifestations of the post-thrombotic syndrome became apparent within the first 2 years after the acute thrombosis. These findings, which challenge the general view that the symptoms of the post-thrombotic syndrome require a long time to become manifest [24], suggest that the duration of follow-up in our patients might be adequate to give a valid estimate of the overall incidence of the syndrome. Although we had expected that the extent of the initial deep venous thrombosis and the degree of occlusiveness would be related to the risk for developing the post-thrombotic syndrome [3, 24, 26], we could not show such a relation. However, patients with recurrent ipsilateral deep venous thrombosis had a significantly increased risk for developing the post-thrombotic syndrome.
Mortality was high (30% after 8 years), and most deaths occurred during the first year in patients with underlying cancer. These data are fully consistent with the results of a similar study among patients with pulmonary embolism [27].
Because our center is a diagnostic facility for all general practitioners in the area, we believe that our observations reflect the true clinical course of symptomatic deep venous thrombosis in outpatients. Venography, the reference standard, was used to diagnose deep venous thrombosis. The diagnosis was confirmed in approximately 35% of patients referred for suspected deep venous thrombosis. The demographic and clinical characteristics of our patients are similar to those in other large series of patients with symptomatic deep venous thrombosis. Although treatment regimens slightly varied, patients were treated according to standard practice. Furthermore, patients were followed prospectively, and few patients were lost to follow-up. Finally, predefined criteria were strictly applied to the diagnosis of recurrent venous thromboembolism, and a validated scale was used to assess the post-thrombotic syndrome.
What do our findings imply for the management of patients with deep venous thrombosis? The high incidence of recurrent venous thromboembolism after cessation of anticoagulant therapy suggests that prolongation of this treatment could be considered in selected patients, depending on the presence of risk factors for recurrent venous thromboembolism. However, the recommendation to use prolonged anticoagulation in these patients can only be based on the results of a large trial addressing the reduction of the number of cases of venous thromboembolism relative to the increased risk for warfarin-related bleeding. Because recurrent venous thrombosis strongly predicted the development of the post-thrombotic syndrome, the prevention of recurrent deep venous thrombosis might be a key to decreasing the incidence of this condition.
We conclude that deep venous thrombosis carries a high risk for recurrent venous thromboembolism that persists for many years, especially in patients without transient risk factors for deep venous thrombosis. The post-thrombotic syndrome occurs in almost one third of patients with deep venous thrombosis and is strongly related to ipsilateral recurrent deep venous thrombosis. Our findings challenge the widely adopted use of short-course anticoagulant therapy in patients with symptomatic deep venous thrombosis.
Dr. Lensing: Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, F-4, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands.
Dr. Prins: Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, B-2 Meibergdreef 9, Amsterdam 1105 A2, the Netherlands.
Author and Article Information
|
|---|
|
TopMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
References
|
|---|
|
TopMethodsResultsDiscussionAuthor & Article InfoReferences |
|---|
1. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand. 1980; 146:267-9.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective on the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991; 151:933-8.[Abstract]
3. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1993:1275-96.
4. Salzman EW, Hirsh J, Marder VJ. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1993:1346-66.
5. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med. 1995; 155:601-7.
6. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995; 332:1661-5.
7. Beyth RJ, Cohen AM, Landefeld S. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995; 155:1031-7.
8. Lensing AW, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989; 320:342-5.
9. Hirsh J, Prins MH, Samama M. Approach to the thrombophilic patient for hemostasis and thrombosis: basic principles and clinical practice. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1993:1543-61.
10. Lensing AW, Buller HR, Prandoni P, Batchelor D, Molenaar AH, Cogo A, et al. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. Thromb Haemostas. 1992; 67:8-12.
11. Lensing AW, Hirsh J, Buller HR. Diagnosis of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1993:1297-321.
12. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation. 1993; 88(4 Pt 1):1730-5.
13. Hirsh J, Bettman M, Coates G, Hull RD. Diagnosis of pulmonary embolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott; 1993:1322-30.
14. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339:441-5.
15. Villalta S, Bagatella P, Piccioli A, Lensing AW, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [Abstract]. Haemostasis. 1994; 24(Suppl 1):158a.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: J Wiley. New York; 1980:1-221.
17. Prandoni P, Lensing AW, Buller HR, Cogo A, Catellan AM, Cuppini S, et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992; 327:1128-33.
18. Gjores J. The incidence of venous thrombosis and its sequelae in certain districts of Sweden. Acta Chir Scand. 1956; 206(Suppl 1):1-88.
19. O'Donnell TF Jr, Browse NL, Burnand KG, Thomas ML. The socioeconomic effects of an iliofemoral venous thrombosis. J Surg Res. 1977; 22:483-8.
20. Strandness DE Jr, Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis. JAMA. 1983; 250:1289-92.[Abstract]
21. Widmer LK, Zemp E, Widmer MT, Schmitt HE, Brandenberg E, Voelin R, et al. Late results in deep vein thrombosis of the lower extremity. Vasa. 1985; 14:264-8.
22. Lindner DJ, Edwards JM, Phinney ES, Taylor LM Jr, Porter JM. Longterm hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J. Vasc Surg. 1986; 4:436-42.
23. Heldal M, Seem E, Sandset PM, Abildgaard U. Deep vein thrombosis: a 7-year follow-up study. J Intern Med. 1993; 234:71-5.
24. Immelman EJ, Jeffrey PC. The postphlebitic syndrome. Pathophysiology, prevention and management. Clin Chest Med. 1984; 5:537-50.
25. Brandjes DP, Heijboer H, de Rijk M, Jagt H, ten Cate JW. The effect of graded compression stockings on the development of the post-thrombotic syndrome in patients with proximal deep-vein thrombosis [Abstract]. Thromb Haemostas. 1991; 65(Suppl):1568a.
26. Monreal M, Martorell A, Callejas JM, Valls R, Llamazares JF, Lafoz E, et al. Venographic assessment of deep vein thrombosis and risk of developing post-thrombotic syndrome: a prospective study. J Intern Med. 1993; 233:233-8.
27. Carson JL. Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992; 326:1240-5.
This article has been cited by other articles:
|
|
 |
|
  G. Camporese, E. Bernardi, P. Prandoni, F. Noventa, F. Verlato, P. Simioni, K. Ntita, G. Salmistraro, C. Frangos, F. Rossi, et al. Low-Molecular-Weight Heparin versus Compression Stockings for Thromboprophylaxis after Knee Arthroscopy: A Randomized Trial Ann Intern Med, July 15, 2008; 149(2): 73 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Strauss, K. A. Egol, M. Alaia, D. Hansen, M. Bashar, and D. Steiger The use of retrievable inferior vena cava filters in orthopaedic patients J Bone Joint Surg Br, May 1, 2008; 90-B(5): 662 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Vedantham Superficial venous interventions: assessing the risk of DVT Phlebology, April 1, 2008; 23(2): 53 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Janjigian and B. E. Muhs Current Treatment of Acute Lower Extremity Deep Venous Thrombosis International Journal of Lower Extremity Wounds, March 1, 2008; 7(1): 15 - 20. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Heit The Epidemiology of Venous Thromboembolism in the Community Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 370 - 372. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Spencer, J. M. Gore, D. Lessard, J. D. Douketis, C. Emery, and R. J. Goldberg Patient Outcomes After Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Venous Thromboembolism Study Arch Intern Med, February 25, 2008; 168(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chang, C. C. Chen, A. Kam, E. Mao, T. H. Shawker, and M. K. Horne III Deep Vein Thrombosis of Lower Extremity: Direct Intraclot Injection of Alteplase Once Daily with Systemic Anticoagulation--Results of Pilot Study Radiology, February 1, 2008; 246(2): 619 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Khorana The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients Oncologist, November 1, 2007; 12(11): 1361 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Silverstein, K. A. Bauer, M. Cushman, C. T. Esmon, W. B. Ershler, and R. P. Tracy Venous thrombosis in the elderly: more questions than answers Blood, November 1, 2007; 110(9): 3097 - 3101. [Full Text] [PDF]
|
|
|
|
 |
|
 The van Gogh Investigators Extended Prophylaxis of Venous Thromboembolism with Idraparinux N. Engl. J. Med., September 13, 2007; 357(11): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Lin, S. Bhatt, D. Rubens, and V. S. Dogra The Importance of Monophasic Doppler Waveforms in the Common Femoral Vein: A Retrospective Study J. Ultrasound Med., July 1, 2007; 26(7): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Cronin, D. G. Lohan, M. Keane, C. Roche, and J. M. Murphy Prevalence and Significance of Asymptomatic Venous Thromboembolic Disease Found on Oncologic Staging CT Am. J. Roentgenol., July 1, 2007; 189(1): 162 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Goldenberg, J. D. Durham, R. Knapp-Clevenger, and M. J. Manco-Johnson A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children Blood, July 1, 2007; 110(1): 45 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Brighton, J. Janssen, and S. P. Butler Aging of Acute Deep Vein Thrombosis Measured by Radiolabeled 99mTc-rt-PA J. Nucl. Med., June 1, 2007; 48(6): 873 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Huerta, S. Johansson, M.-A. Wallander, and L. A. Garcia Rodriguez Risk Factors and Short-term Mortality of Venous Thromboembolism Diagnosed in the Primary Care Setting in the United Kingdom Arch Intern Med, May 14, 2007; 167(9): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simanek, R. Vormittag, M. Hassler, K. Roessler, M. Schwarz, C. Zielinski, I. Pabinger, and C. Marosi Venous thromboembolism and survival in patients with high-grade glioma Neuro-oncol, April 1, 2007; 9(2): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I A Campbell, D P Bentley, R J Prescott, P A Routledge, H G M Shetty, and I J Williamson Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial BMJ, March 31, 2007; 334(7595): 674 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Labropoulos, P. J. Patel, J. E. Tiongson, L. Pryor, L. R. Leon Jr, and A. K. Tassiopoulos Patterns of Venous Reflux and Obstruction in Patients With Skin Damage Due to Chronic Venous Disease Vascular and Endovascular Surgery, February 1, 2007; 41(1): 33 - 40. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Prandoni, F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, R. Pesavento, M. Iotti, D. Tormene, P. Simioni, and A. Pagnan The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients Haematologica, February 1, 2007; 92(2): 199 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mismetti, K. Rivron-Guillot, S. Quenet, H. Decousus, S. Laporte, M. Epinat, and F. G. Barral A Prospective Long-term Study of 220 Patients With a Retrievable Vena Cava Filter for Secondary Prevention of Venous Thromboembolism Chest, January 1, 2007; 131(1): 223 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. O'Connell, W. D. Boswell, V. Duddalwar, A. Caton, L. S. Mark, C. Vigen, and H. A. Liebman Unsuspected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance J. Clin. Oncol., October 20, 2006; 24(30): 4928 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. MacDougall, A. L. Feliu, S. J. Boccuzzi, and J. Lin Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am. J. Health Syst. Pharm., October 15, 2006; 63(20 Suppl 6): S5 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Singh Mangat, A. Mehra, I. Yunas, and K. Porter Venous thromboprophylaxis in trauma: a review Trauma, October 1, 2006; 8(4): 233 - 247. [Abstract] [PDF]
|
|
|
|
 |
|
 A Fennerty Venous thromboembolic disease and cancer. Postgrad. Med. J., October 1, 2006; 82(972): 642 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Casele and W. A. Grobman Cost-effectiveness of Thromboprophylaxis With Intermittent Pneumatic Compression at Cesarean Delivery. Obstet. Gynecol., September 1, 2006; 108(3): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hron, M. Kollars, B. R. Binder, S. Eichinger, and P. A. Kyrle Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA, July 26, 2006; 296(4): 397 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Ho, G. J. Hankey, D. J. Quinlan, and J. W. Eikelboom Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, April 10, 2006; 166(7): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Alcalay, T. Wun, V. Khatri, H. K. Chew, D. Harvey, H. Zhou, and R. H. White Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival J. Clin. Oncol., March 1, 2006; 24(7): 1112 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 711 - 718.
|
|
|
|
|
|
P. Prandoni How I treat venous thromboembolism in patients with cancer Blood, December 15, 200 |
Article
